Blockade of ErbB2/3 by the biparatopic DARPin consistently attenuated Src activity (Fig. 4c); conversely, the inhibition of Src alone or in combination with trastuzumab does not trigger apoptosis in the 3D tumour model and does not induce PARP cleavage. This evidence concerns the gene ERBB2 and neoplasm.